150 related articles for article (PubMed ID: 12187506)
21. Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.
Casado JL; Moreno S; Hertogs K; Dronda F; Antela A; Dehertogh P; Perez-Elías MJ; Moreno A;
AIDS; 2002 Jan; 16(1):47-52. PubMed ID: 11741162
[TBL] [Abstract][Full Text] [Related]
22. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
[TBL] [Abstract][Full Text] [Related]
23. HIV genotype mutations evoked by nelfinavir-based regimens: frequency, background, and consequences on subsequent treatment options.
Manfredi R; Calza L
J Acquir Immune Defic Syndr; 2002 Jun; 30(2):258-60. PubMed ID: 12045690
[No Abstract] [Full Text] [Related]
24. Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.
Su CT; Ling WL; Lua WH; Haw YX; Gan SK
BMC Bioinformatics; 2016 Dec; 17(Suppl 19):500. PubMed ID: 28155724
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and virologic consequences of HIV-1 genotype mutations detected in a cohort of 161 Italian patients receiving a nelfinavir-based highly active antiretroviral therapy.
Calza L; Borderi M; Farneti B; Tampellini L; Re MC; Monari P; Bon I; Chiodo F
J Chemother; 2003 Apr; 15(2):165-72. PubMed ID: 12797395
[TBL] [Abstract][Full Text] [Related]
26. Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants.
Perrin V; Mammano F
J Virol; 2003 Sep; 77(18):10172-5. PubMed ID: 12941931
[TBL] [Abstract][Full Text] [Related]
27. Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.
Svedhem V; Lindkvist A; Lidman K; Sönnerborg A
J Med Virol; 2002 Dec; 68(4):473-8. PubMed ID: 12376953
[TBL] [Abstract][Full Text] [Related]
28. Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor.
Gianotti N; Tambussi G; Boeri E; Lazzarin A
J Biol Regul Homeost Agents; 2001; 15(2):166-9. PubMed ID: 11501975
[TBL] [Abstract][Full Text] [Related]
29. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
Clemente JC; Hemrajani R; Blum LE; Goodenow MM; Dunn BM
Biochemistry; 2003 Dec; 42(51):15029-35. PubMed ID: 14690411
[TBL] [Abstract][Full Text] [Related]
30. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
[TBL] [Abstract][Full Text] [Related]
31. Molecular basis for reduced cleavage activity and drug resistance in D30N HIV-1 protease.
Bihani SC; Gupta GD; Hosur MV
J Biomol Struct Dyn; 2022; 40(23):13127-13135. PubMed ID: 34609269
[TBL] [Abstract][Full Text] [Related]
32. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
[TBL] [Abstract][Full Text] [Related]
33. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
34. Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naïve patients treated with NFV-containing regimens in an HIV clinic cohort.
Tsuchiya K; Matsuoka-Aizawa S; Yasuoka A; Kikuchi Y; Tachikawa N; Genka I; Teruya K; Kimura S; Oka S
J Clin Virol; 2003 Aug; 27(3):252-62. PubMed ID: 12878089
[TBL] [Abstract][Full Text] [Related]
35. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G.
Abecasis AB; Deforche K; Snoeck J; Bacheler LT; McKenna P; Carvalho AP; Gomes P; Camacho RJ; Vandamme AM
AIDS; 2005 Nov; 19(16):1799-806. PubMed ID: 16227787
[TBL] [Abstract][Full Text] [Related]
36. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
Kakehasi FM; Tupinambás U; Cleto S; Aleixo A; Lin E; Melo VH; Aguiar RA; Pinto JA
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1515-20. PubMed ID: 18160009
[TBL] [Abstract][Full Text] [Related]
37. The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors.
Santos AF; Soares MA
Mem Inst Oswaldo Cruz; 2011 Mar; 106(2):177-81. PubMed ID: 21537677
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 protease-substrate coevolution in nelfinavir resistance.
Kolli M; Ozen A; Kurt-Yilmaz N; Schiffer CA
J Virol; 2014 Jul; 88(13):7145-54. PubMed ID: 24719428
[TBL] [Abstract][Full Text] [Related]
39. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
Toor JS; Sharma A; Kumar R; Gupta P; Garg P; Arora SK
Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]